Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-01-12 M&A Activity
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
广发证券股份有限公司关于公司本次交易产业政策和交易类型之独立财务顾问核查意见
M&A Activity Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding a major asset restructuring transaction involving issuance of shares and cash payment to acquire a 90% stake in another company. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, discusses industry classification, transaction type, control changes, shareholding structure before and after the transaction, and compliance with regulatory requirements. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a specialized report related to a merger/acquisition transaction, specifically a major asset restructuring and share issuance. Therefore, the document fits best under the category of M&A Activity (TAR) which covers announcements and documents related to merger proposals or takeover bids.
2018-01-12 Chinese
独立财务顾问承诺函
Regulatory Filings Classification · 95% confidence The document is titled as an "Independent Financial Advisor Commitment Letter" related to a company's issuance of shares and cash payment for asset acquisition and related party transactions. It contains statements of due diligence, compliance with laws and regulations, and confidentiality measures by the financial advisor. The document is short (740 characters) and does not contain any financial statements, detailed financial data, or report content. It is a formal attestation or certification by the financial advisor rather than a full report or announcement of financial results. It does not fit categories like Annual Report, Interim Report, or Capital/Financing Update directly. Given the nature of the document as a formal attestation letter by an advisor, it best fits under Regulatory Filings (RNS), which is the fallback for such compliance and certification documents.
2018-01-12 Chinese
上海睿智化学研究有限公司截至2017年9月30日止9个月期间、2016年度及2015年度财务报表及审计报告（已取消）
Annual Report Classification · 95% confidence The document contains detailed financial statements including consolidated and company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the periods ending September 30, 2017 (9 months), and full years 2016 and 2015. It also includes audit reports and extensive financial notes. The presence of audited financial statements for multiple periods and comprehensive financial data indicates this is a full annual report or a combined annual and interim report. Given the inclusion of multiple years and the audit report, this aligns with the characteristics of an Annual Report (10-K equivalent). The document length (15,000 characters) and detailed financial data confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is Annual Report (10-K).
2018-01-12 Chinese
关于与招商银行股份有限公司佛山分行签订《战略合作协议》的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement about signing a strategic cooperation agreement between the company and a bank, detailing the nature of the agreement, potential credit lines, risks, and future cooperation plans. It does not contain financial statements, audit information, or detailed financial results. It is not a report but a corporate announcement about financing cooperation. The document length is short (1993 characters), and it is clearly an announcement of a financing update rather than a full report or detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP).
2018-01-05 Chinese
关于终止投资设立量子巧乐医疗产业投资基金暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the termination of an investment in establishing a medical industry investment fund and related connected transactions. It includes details about board meetings, shareholder approvals, independent directors' opinions, and regulatory compliance references. The document is relatively short (2069 characters) and focuses on a corporate action announcement rather than financial results or detailed financial data. It does not contain financial statements or detailed financial analysis. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a proxy solicitation or voting results announcement. The content fits best with a Regulatory Filing (RNS) as it is a formal disclosure of a corporate event and related governance matters without being a full report or financial statement.
2018-01-04 Chinese
第三届监事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a supervisory board meeting of Quantum Hi-Tech (China) Biological Co., Ltd. It details the decision to terminate an investment project and mentions the voting results of the supervisory board members. The document is short (868 characters) and does not contain financial statements or detailed financial data. It is not an annual report, interim report, earnings release, or any detailed financial or management report. It is also not a notice of dividend, capital change, or merger activity. The document is a formal announcement of a board/management decision, specifically a supervisory board resolution. Therefore, it fits best under Board/Management Information (MANG).
2018-01-04 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.